CERT1 and cancer: For instance, CERT is overexpressed in ovarian cancer cells (Juul et al., 2010) and HER+ cells (Lee et al., 2012); its silencing exerts enhanced sensitivity to multi-drug treatment in several cancer cell lines (Swanton et al., 2007) and also induces changes in the levels of lysosome-associated membrane protein 2, which increases the autophagosome–lysosome flux in colorectal and breast cancer cell lines (Lee et al., 2012).